Didanosine (ddI) is a nucleoside reverse transcriptase inhibitor (NRTI) used in HIV treatment, working by blocking the reverse transcriptase enzyme to stop viral replication. Developed in the late 1970s early 1980s as part of research on nucleoside analogs for retroviral infections, it was approved in the late 1980s and became an important component of combination antiretroviral therapy (HAART). Although it effectively reduces viral load and slows disease progression, its use has declined over time due to newer drugs with better safety profiles and fewer side effects.
Image
